This is an aggregated industry headline. Read the full story at Pharmaceutical Technology →
Apertura and NIH institutes to test gene therapy for NPC1
Apertura has entered a CRADA with various NIH institutes for a gene therapy to treat Niemann-Pick Disease Type C1 (NPC1).
By Pharmaceutical Technology
· Jul 10, 2026
· via Pharmaceutical Technology
Image: Pharmaceutical Technology
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlinePharmaceutical Technology
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Bleeding disorder patient groups put Sobi, Roche and Novo Nordisk on the podium in 2025/2026's corporate reput…
The WeekFierceBiotech ↗
The Advanced Research Projects Agency for Health has awarded a new tranche of funds for companies and institut…
The WeekBriefing
The August 5 meeting will explore how to identify and prioritize FDA-approved drugs for new indications and po…